Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintains a $7 price target.

April 11, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Taysha Gene Therapies with a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively influence Taysha Gene Therapies' stock price in the short term. Analyst ratings, especially with a Buy recommendation, can lead to increased investor interest and potentially drive up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100